Immune tolerance induction in haemophilia A patients with inhibitor using Fc fusion recombinant factor VIII product
Author:
Affiliation:
1. Department of Hematology, Ogikubo Hospital
2. Department of Laboratory Medicine, Tokyo Medical University Hospital
3. Molecular Genetics of Coagulation Disorders, Tokyo Medical University Hospital
Publisher
Japanese Society on Thrombosis and Hemostasis
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jjsth/29/3/29_2018_JJTH_29_3_307-314/_pdf
Reference12 articles.
1. 1) Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group: Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 13: 373–379, 2007.
2. 2) Kenet G, Oladapo A, Epstein JD, Thompson C, Novack A, Nugent DJ: Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. Haemophilia 23: e394–e402, 2017.
3. 3) Krishnamoorthy S, Liu T, Drager D, Patarroyo-White S, Chhabra ES, Peters R, Josephson N, Lillicrap D, Blumberg RS, Pierce GF, Jiang H: Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol 301: 30–39, 2016.
4. 4) Malec LM, Journeycake J, Ragni MV: Extended half-life factor VIII for immune tolerance induction in haemophilia. Haemophilia 22: e552-e554, 2016.
5. 5) Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee: First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia 22: 87–95, 2016.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3